In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2186-2192

  Williams, Stephanie L ^a   Hartline, Caroll B ^a   Kushner, Nicole L ^a   Harden, Emma A ^a   Bidanset, Deborah J ^a   Drach, John C ^b   Townsend, Leroy B ^b   Underwood, Mark R ^c   Biron, Karen K ^c   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO 1 (BETA DEXTRO RIBOFURANOSYL)BENZIMIDAZOLE; ACICLOVIR; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; GW 275175X; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SYNTHESIS INHIBITION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HERPESVIRUS 6, HUMAN; HERPESVIRUS 8, HUMAN; RIBONUCLEOSIDES; VIRUS REPLICATION;

EID: 0037974682     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2186-2192.2003     Document Type: Article

References (36)

1. Beadle, J. R., C. B. Hartline, K. A. Aldern, N. Rodriguez, E. A. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
2. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
3. Bogner, E., K. Radsak, and M. F. Stinski. 1998. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol. 72:2259-2264.
4. Chrisp, P., and S. P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties, and the therapeutic use in immuno-compromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
5. Chulay, J., K. K. Biron, L. Wang, M. Underwood, S. Chamberlain, L. Frick, S. Good, M. Davis, R. Harvey, L. Townsend, J. Drach, and G. Koszalka. 1999. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exper. Med. Biol. 458:129-134.
6. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729.
7. Curran, M., and S. Noble. 2001. Valganciclovir. Drugs 61:1145-1150.
8. Davison, A. J. 1992. Channel catfish virus: a new type of herpesvirus. Virology 186:9-14.
9. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
10. Field, A. K., and K. K. Biron. 1991. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1-13.
11. Gershburg, E., and J. S. Pagano. 2002. Phosphorylation of Epstein-Barr (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J. Virol. 76:998-1003.
12. Good, S. S., B. S. Owens, L. B. Townsend, and J. C. Drach. 1994. The disposition in rats and monkeys of 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)-benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antiviral Res. 23:(Suppl. I)103.
13. Gudmundsson, K. S., J. Tidwell, N. Lippa, G. W. Koszalka, N. van Draanen, R. G. Ptak, J. C. Drach, and L. B. Townsend. 2000. Synthesis and antiviral evaluation of halogenated β-D- and L-erythrofuranosylbenzimidazoles. J. Med. Chem. 43:2464-2472.
14. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir. Chem. Chemother. 7:115-127.
15. Hwang, J. S., and E. Bogner. 2002. ATPase activity of the terminase subunit pUL56 of human cytomegalovirus. J. Biol. Chem. 277:6943-6948.
16. Koszalka, G. W., S. D. Chamberlain, R. J. Harvey, L. W. Frick, S. S. Good, M. L. Davis, A. Smith, J. C. Drach, L. B. Townsend, and K. K. Biron. 1996. Benzimidazoles for the treatment of human cytomegalovirus infections. Antivir. Res. 30:A43.
17. Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron. 2002. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46:2373-2380.
18. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
19. Krosky, P. M., R. G. Ptak, M. R. Underwood, K. K. Biron, L. B. Townsend, and J. C. Drach. 2000. Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne. Antivir. Chem. Chemother. 11:349-352.
20. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
21. McSharry, J. J., A. McDonough, B. Olson, C. Talarico, M. Davis, and K. K. Biron. 2001. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol. 8:1279-1281.
22. Mocarski, E. S., Jr., and C. Tan Courcelle. 2001. Cytomegaloviruses and their replication, p. 2629-2673. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott, Williams & Wilkins, Philadelphia, Pa.
23. Nassiri, M. R., S. G. Emerson, R. V. Devivar, L. B. Townsend, J. C. Drach, and R. S. Taichman. 1996. Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells. Br. J. Haematol. 93:273-279.
24. Perry, C. M., and J. A. Barman Balfour. 1999. Fomivirsen. Drugs 57:375-380.
25. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
26. Prichard, M. N., S. R. Turk, L. A. Coleman, S. L. Engelhardt, C. Shipman, Jr., and J. C. Drach. 1990. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 28:101-106.
27. Rybak, R. J., C. B. Hartline, Y.-L. Qiu, J. Zemlicka, E. A. Harden, G. Marshall, J.-P. Sommadossi, and E. R. Kern. 2000. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob. Agents Chemother. 44:1506-1511.
28. Scheffczik, H., C. G. W. Savva, A. Holzenburg, L. Kolesnikova, and E. Bogner. 2002. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 30:1695-1703.
29. Scholz, B., S. Rechter, J. C. Drach, L. B. Townsend, and E. Bogner. 2003. Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res. 31:1426-1433.
30. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 38:4098-4105.
31. Townsend, L. B., K. S. Gudmundsson, S. M. Daluge, J. J. Chen, Z. Zhu, G. W. Koszalka, L. Boyd, S. D. Chamberlain, G. A. Freeman, K. K. Biron, and J. C. Drach. 1999. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucleosides Nucleotides 18:509-519.
32. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
33. Wang, L. H., R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire. 2003. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1334-1342.
34. Whitley, R. J. 2001. Herpes simplex viruses, p. 2461-2509. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott, Williams & Wilkins. Philadelphia, Pa.
35. Zacny, V. L., E. Gershburg, M. G. Davis, K. K. Biron, and J. S. Pagano. 1999. Inhibition of Epstein-Barr replication by benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1-H benzimidazole. J. Virol. 73:7271-7277.
36. Zou, R., R. Ayres, J. C. Drach, and L. B. Townsend. 1996. Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. J. Med. Chem. 39:3477-3482.